ArticleCureus2025
A Phase I Study of Nimotuzumab With Nivolumab in Advanced Non-small Cell Lung Cancer and Head and Neck Squamous Cell Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionNimotuzumab is a monoclonal antibody (mAb) that targets the epidermal growth factor receptor. Nivolumab is an anti-programmed death 1 (anti-PD1) mAb that overcomes immune checkpoint inhibition. This trial aimed to evaluate the safety, tolerability, and efficacy of combination treatment as second-line therapy in non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC).
methodsThis was a single-center, single-arm, non-randomized study utilizing a three plus three dose escalation design. Nimotuzumab was given intravenously (IV) at escalating doses of 200 mg, 300 mg, and 400 mg after nivolumab infusion at 240 mg IV every two weeks in a 28-day cycle. Recommended phase 2 dose (RP2D) and dose-limiting toxicities (DLT) were determined. Treatment was continued until disease progression, unacceptable toxicity, or withdrawal from the trial. Serial EKG and troponin checks were performed.
resultsSeven patients were enrolled across the 200 mg and 300 mg nimotuzumab dose levels. The median age was 64.1 years. Four patients (57.1%) were males. Five (71.4%) had NSCLC, and the predominant histology was pure adenocarcinoma (n = 4, 57.1%). Four patients (57.1%) had Kirsten rat sarcoma (KRAS) mutation. All patients had disease progression after platinum-based and anti-PD1 therapy prior to enrollment, except for two NSCLC patients who were enrolled to receive this treatment after initial platinum-based chemotherapy only. Four patients (two from each dose level) had troponin elevation (median = 0.1 ng/ml, range = 0.07 to 0.3 ng/ml) lasting at least 24 hours, which normalized next week without any associated chest pain, except for one patient (HNSCC) with potential treatment-related DLT. Disease control rate was 42.9% (stable disease as best response, n = 3).
conclusionsAsymptomatic troponin elevation was seen with this combination treatment. While there were no clinically significant adverse cardiac outcomes, further development was terminated due to the competitive landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.